Wednesday, January 26, 2011
clinical trial: Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The aim of this study is to determine the frequency of the three most common BRCA1 and BRCA2 genetic mutations that are commonly found in Ashkenazi Jewish patients with pancreatic cancer. Testing for BRCA1 and BRCA2 mutations in relatives of hereditary pancreatic cancer patients may have a significant impact; allowing for early screening, treatment, and resection of pre-malignant tissue or malignant lesions.
clinical trial: Anonymous Testing of Pathology Specimens for BRCA (and Lynch Syndrome MSH2) Mutations in Ashkenazi Jewish Individuals Who Have Cancer
|Extrahepatic Bile Duct Cancer|
free full access: Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients — Ann Oncol
"It seems astonishing that in the 21st century decisions on health care can still be made without a solid grounding in research evidence. This is true even in clinical research, whether for simple or complex interventions , where systematic reviews time and time again conclude that the evidence base is inadequate . It is even more true in the areas of health policy and health systems, where quality research is hampered further by a lack of shared definitions, a lack of consensus on guiding principles, poor capacity (especially in low-resource regions), and methodological challenges ,.
The World Health Report (WHR) for 2012 will be on the theme of “No Health without Research”. This flagship report from WHO will, for the first time in its history, focus on research for better health. The primary target audience of the report will be ministers of health in the WHO member states, and the goal of the report is to provide new ideas, innovative thinking, and pragmatic advice for member states on how to strengthen their own health research systems. The report will have the three following aims.
- To show that research is important for meeting health needs and improving health outcomes;
- To encourage countries to therefore invest more resources in developing and strengthening their national health research systems;
- To argue that countries should not see research as an expense or as an afterthought, but as an investment for a better, healthier future.....cont'd
Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the RIETE Registry (abstract)
Note: different adverse events depending on cancer site
FDA review indicates possible association between breast implants and a rare cancer (see Blogger's Notes on this issue)
Blogger's Notes: for background information regarding the long standing health issues concerning breast implants do a 'litigation' search. Past research on
the issue of risk/breast implants (noncancer/cancer issues) includes many
lawsuits, the latter of which were settled by some of the manufacturers without admission of fault (guilt). The past lawsuits (class action suits) were based on the older forms of implants.
Takeda Pharmaceutical and the Takeda Oncology Company: Millennium, have commenced TRINOVA-1 Phase III clinical trial on anti-cancer agent AMG 386 in Japan
American Society of Clinical Oncology Statement: Toward Individualized Care for Patients With Advanced Cancer — JCO
Addition of Bevacizumab to Chemotherapy for Treatment of Solid Tumors: Similar Results but Different Conclusions
Table 1. Randomized Phase III Studies Comparing Chemotherapy With or Without Bevacizumab As First-Line Chemotherapy for Advanced Epithelial Cancers